Literature DB >> 12108917

Administration of either anti-CD40 or interleukin-12 following lethal total body irradiation induces acute lethal toxicity affecting the gut.

Julie A Hixon1, Miriam R Anver, Bruce R Blazar, Angela Panoskaltsis-Mortari, Robert H Wiltrout, William J Murphy.   

Abstract

Interleukin (IL)-12 and antibodies against CD40 have demonstrated antitumor effects in a variety of in vivo model systems. However, both agents can also mediate significant toxicities either when used following lethal TBI or when administered in combination with other agents such as IL-2. In this study, we assessed the effects of anti-CD40 monoclonal antibody (MoAb) and IL-12 in lethally irradiated mice. Acute lethal toxicity was observed following the administration of either 10 microg anti-CD40 MoAb (FGK45) or 0.5 microg of recombinant murine (rm)IL-12 that resulted in 100% mortality of all mice within 4 to 6 days. Histological evaluation revealed destruction of the normal gut architecture in both anti-CD40 MoAb- and rmIL-12-treated mice. Analysis of serum cytokine levels in the lethally irradiated mice receiving anti-CD40 MoAb demonstrated a marked increase of interferon (IFN)-gamma and IL-12 p40, whereas mice receiving rmIL-12 demonstrated a marked increase of IFN-gamma. Lethally irradiated IL-12 p40 knock-out mice were resistant to anti-CD40-induced toxicity, suggesting that the lack of IL-12 p40 with no possibility of making functional IL- 12 p70 is key for this toxic reaction. Similarly, lethally irradiated IFN-gamma knock-out mice were completely resistant to rmIL-12-induced toxicity, suggesting that IFN-gamma is a major player in IL-12-mediated toxicity. These results suggest that both anti-CD40 MoAb and rmIL-12 induce an acute fatal toxicity characterized by similar intestinal pathology and mediated in part by IFN-gamma.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12108917

Source DB:  PubMed          Journal:  Biol Blood Marrow Transplant        ISSN: 1083-8791            Impact factor:   5.742


  8 in total

1.  A potent adjuvant effect of CD40 antibody attached to antigen.

Authors:  Tom A Barr; Adele L McCormick; Jennifer Carlring; Andrew W Heath
Journal:  Immunology       Date:  2003-05       Impact factor: 7.397

2.  Eradication of solid tumors using histone deacetylase inhibitors combined with immune-stimulating antibodies.

Authors:  Ailsa J Christiansen; Alison West; Kellie-Marie Banks; Nicole M Haynes; Michele W Teng; Mark J Smyth; Ricky W Johnstone
Journal:  Proc Natl Acad Sci U S A       Date:  2011-02-22       Impact factor: 11.205

Review 3.  Engineering nano- and microparticles to tune immunity.

Authors:  James J Moon; Bonnie Huang; Darrell J Irvine
Journal:  Adv Mater       Date:  2012-05-29       Impact factor: 30.849

4.  MHC Class II Antigen Presentation by the Intestinal Epithelium Initiates Graft-versus-Host Disease and Is Influenced by the Microbiota.

Authors:  Motoko Koyama; Pamela Mukhopadhyay; Iona S Schuster; Andrea S Henden; Jan Hülsdünker; Antiopi Varelias; Marie Vetizou; Rachel D Kuns; Renee J Robb; Ping Zhang; Bruce R Blazar; Ranjeny Thomas; Jakob Begun; Nicola Waddell; Giorgio Trinchieri; Robert Zeiser; Andrew D Clouston; Mariapia A Degli-Esposti; Geoffrey R Hill
Journal:  Immunity       Date:  2019-09-18       Impact factor: 31.745

5.  A novel form of 4-1BBL has better immunomodulatory activity than an agonistic anti-4-1BB Ab without Ab-associated severe toxicity.

Authors:  Rich-Henry Schabowsky; Kutlu G Elpek; Shravan Madireddi; Rajesh K Sharma; Esma S Yolcu; Laura Bandura-Morgan; Robert Miller; Kathryn J MacLeod; Robert S Mittler; Haval Shirwan
Journal:  Vaccine       Date:  2009-10-29       Impact factor: 3.641

Review 6.  ProtEx technology for the generation of novel therapeutic cancer vaccines.

Authors:  Rich-Henry Schabowsky; Rajesh K Sharma; Shravan Madireddi; Abhishek Srivastava; Esma S Yolcu; Haval Shirwan
Journal:  Exp Mol Pathol       Date:  2009-01-31       Impact factor: 3.362

7.  Induction of potent anti-tumor responses while eliminating systemic side effects via liposome-anchored combinatorial immunotherapy.

Authors:  Brandon Kwong; Haipeng Liu; Darrell J Irvine
Journal:  Biomaterials       Date:  2011-04-22       Impact factor: 12.479

8.  Mechanical disruption of tumors by iron particles and magnetic field application results in increased anti-tumor immune responses.

Authors:  Myriam N Bouchlaka; Gail D Sckisel; Danice Wilkins; Emanual Maverakis; Arta M Monjazeb; Maxwell Fung; Lisbeth Welniak; Doug Redelman; Alan Fuchs; Cahit A Evrensel; William J Murphy
Journal:  PLoS One       Date:  2012-10-25       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.